|
Rick E Winningham
Rick E Winningham joined Theravance as Chief Executive Officer and a member of our board of directors in October 2001. From 1997 to 2001 he served as President, Bristol-Myers Squibb Oncology/Immunology/ Oncology Therapeutics Network (OTN) and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN at Bristol-Myers Squibb, Mr. Winningham also had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, Oncology/ Metabolics and GU/GI/Neuroscience therapeutic areas. Mr. Winningham held various management positions with Bristol-Myers Squibb and its predecessor, Bristol-Myers, since 1986. Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. degree from Southern Illinois University. |
|
Michael W. Aguiar
Michael W. Aguiar joined Theravance as Senior Vice President and Chief Financial Officer in March 2005. Prior to joining Theravance, Mr. Aguiar served as Vice President of Finance at Gilead Sciences, Inc., a biopharmaceutical company, since 2002. Prior to Gilead Sciences, Inc., Mr. Aguiar served as Vice President of Finance at Immunex Corporation, a biopharmaceutical company, from 2001 to 2002. From 1995 to 2001, he was with Honeywell International in a variety of positions, including, most recently CFO and Vice President Finance for Honeywell Electronic Materials SBU. Mr. Aguiar earned a B.S. in biology from UC Irvine and an M.B.A. in finance from the University of Michigan. |
|
Leonard M. Blum
Leonard M. Blum joined Theravance as Senior Vice President and Chief Commercial Officer in July 2007. Prior to joining Theravance, Mr. Blum served as Senior Vice President of Sales and Marketing at ICOS Corporation. From 1987-2000, Mr. Blum held positions of increasing responsibility in marketing and sales management at Merck & Co. in both U.S. and international markets. Mr. Blum earned an M.B.A. from Stanford University, studied Finance as a Fulbright Fellow at the University of Zurich, and received an A.B. in Economics, magna cum laude, from Princeton University. Mr. Blum served as an officer in the U.S. Army Special Forces. |
|
Arthur L. Campbell, Ph.D.
Arthur L. Campbell, Ph.D., joined Theravance as Senior Vice President, Technical Operations in June 2003. During 2003, he was Vice President, BioPharma at Pfizer, Inc. Prior to joining Pfizer, he was Vice President, BioPharma at Pharmacia Corporation from 2000 until 2003, with global responsibility for Protein API and Drug Product Development and API manufacturing. From 1980 to 2000 Dr. Campbell was employed by Monsanto/Searle, most recently as Vice President, Product Development, R&D. Dr.Campbell holds a Ph.D. in Medicinal Chemistry from the University of Kansas and a B.S. in Chemistry from St. Benedict's College, where he graduated cum laude. |
|
Mathai Mammen, M.D., Ph.D.
Mathai Mammen, M.D., Ph.D., co-founded Theravance in 1996. He was promoted to Senior Vice President, Research, in January 2008. He has served in various positions in both the Medicinal Chemistry Department and the Molecular and Cellular Biology Department, most recently as Vice President, Molecular and Cellular Biology, responsible for all molecular pharmacology, molecular biology, cell biology, microbiology and enzymology activities in support of projects in both Research and Development. Dr. Mammen obtained his M.D. from Harvard Medical School/Massachusetts Institute of Technology, and his Ph.D. in Physical Organic Chemistry from Harvard University's Department of Chemistry. Dr. Mammen obtained his Bachelor's Degree in Chemistry from Dalhousie University in Halifax, Nova Scotia. |
|
Bradford J. Shafer
Bradford J. Shafer joined Theravance as Senior Vice President, General Counsel and Secretary in August 1999. From 1996 to 1999 he served as General Counsel of Heartport, Inc., a cardiovascular medical device company. From 1993 to 1996 Mr. Shafer was a partner in the Business and Technology Group at the law firm of Brobeck, Phleger & Harrison LLP. Mr. Shafer holds a J.D. from the University of California, Hastings College of the Law, where he was Editor-in-Chief of The Hastings Constitutional Law Quarterly, and a B.A. from the University of the Pacific, where he graduated magna cum laude. |
|
Steve Barriere, Pharm.D.
Steve Barriere, Pharm.D., joined Theravance in 2002 as Senior Director, Clinical Research and was promoted to Vice President, Clinical and Medical Affairs in April 2008. Prior to joining Theravance, Dr. Barriere worked in anti-infective development programs at several biopharmaceutical companies. Prior to joining the pharmaceutical industry, Dr. Barriere held academic positions at University of California, San Francisco and University of California, Los Angeles. He is a Fellow of the Infectious Diseases Society of America and the American College of Clinical Pharmacy. Dr. Barriere obtained his Pharm.D. degree from the University of California, San Francisco, and currently holds an academic title at the University of California, San Francisco, where he is a Clinical Professor. |
|
Michael Conner, D.V.M.
Michael Conner, D.V.M., joined Theravance in 1999 as Senior Director of Safety Assessment and Toxicology and was promoted to Vice President, Safety Assessment/ Toxicology in February 2001. Prior to joining Theravance, Dr. Conner worked for ten years at Merck Research Laboratories, most recently serving as a Director of Compound Management within the Department of Safety Assessment. Dr. Conner earned a D.V.M. from the University of Georgia, a B.S. degree in Biology from the Massachusetts Institute of Technology, and completed postdoctoral fellowships at Harvard and MIT prior to serving on the faculty of Boston University School of Medicine. |
|
Dennis O. Driver
Dennis O. Driver joined Theravance as Vice President, Human Resources in October 2007. From 2001 through 2007, Mr. Driver served as Vice President, Human Resources at various companies within the Johnson & Johnson family of businesses including Biosense Webster, Inc., Scios Inc. and Cordis Corporation. Prior to that, he held senior level human resources leadership positions with Peoplesoft, Silicon Graphics, Inc. and Acuson Corporation. He has a wealth of human resources expertise in both domestic and international operations. Mr. Driver holds a B.A. in Business Administration from Stillman College, where he graduated summa cum laude. Mr. Driver served as an officer in the United States Marine Corps. |
|
Michael R. Goldberg, M.D., Ph.D.
Michael R. Goldberg, M.D., Ph.D., joined Theravance as Vice President, Clinical Pharmacology in September of 2005. From 1988 to 2005, Dr. Goldberg held various positions at Merck, initially establishing the clinical pharmacology group at Merck's Pennsylvania site and, for the last 4 1/2 years, as Senior Director of Safety/Clinical Risk Management and Safety Surveillance. Prior to his time at Merck, Dr. Goldberg worked at Eli Lilly in the Clinical Pharmacology Department. He received his M.D. and Ph.D. degrees from Tulane University, School of Medicine and trained there in internal medicine. He completed his Clinical Pharmacology fellowship at Vanderbilt University School of Medicine. |
|
Jeffrey A. Hagenah, Ph.D.
Jeffrey A. Hagenah, Ph.D., joined Theravance in April 2000 as Senior Patent Counsel and was named Chief Patent Counsel in April 2003. He was promoted to Vice President & Chief Patent Counsel in January 2007. Prior to joining Theravance, Dr. Hagenah was an attorney at Burns, Doane, Swecker & Mathis, L.L.P. From 1984 to 1993, he held a variety of positions at Chevron Corporation in the Law Department and in Chevron Chemical Company. Dr. Hagenah holds a J.D. from Boalt Hall at the University of California, Berkeley; a Ph.D. in Chemistry from the University of California, Los Angeles; and a B.S. in Chemistry "With Great Distinction" from California State University, Long Beach. |
|
Sharath S. Hegde, Ph.D.
Sharath S. Hegde, Ph.D., joined the Pharmacology team at Theravance in September 1999 and has held the positions of Associate Director, Director, Senior Director and Executive Director. He was promoted to Vice President in June 2007. Prior to joining Theravance, Dr. Hegde spent 9 years at Syntex Corporation, later acquired by Roche Holdings Ltd. Dr. Hegde obtained his Ph.D. in Pharmacology from the University of Houston and obtained his B.Pharm/M.Pharm degree in Pharmacy/Pharmacology from the University of Bombay. |
|
Dan Marquess, D.Phil.
Dan Marquess, D.Phil., has been Vice President, Medicinal Chemistry since June 2007. Dr. Marquess joined the medicinal chemistry department at Theravance in 1998 and served as Associate Director, Director, Senior Director and Executive Director. Prior to joining Theravance, Dr. Marquess worked in the medicinal chemistry department at GlaxoSmithKline, Stevenage UK from 1994-1998. Dr. Marquess was a NATO post-doctoral fellow at Stanford University. He earned his D.Phil. in Organic Chemistry at the University of Oxford. He holds a B. Sc. in Chemistry from Queen's University of Belfast, N. Ireland. |
|
Edmund J. Moran, Ph.D.
Edmund J. Moran, Ph.D., joined the Research team at Theravance in February 1998 and has held the positions of Associate Director, Director, Senior Director and Vice President, Medicinal Chemistry through 2006. In 2007, Dr. Moran was promoted to Vice President, Exploratory Projects and DMPK/Analytical. Prior to joining Theravance, Dr. Moran founded the medicinal chemistry department at Ontogen Corporation in 1993 and was its first employee. Prior to joining Ontogen, Dr. Moran was an NIH postdoctoral fellow in the laboratories of Professor Peter G. Schultz at U.C. Berkeley from 1992-1993. Dr. Moran obtained his Ph.D. in Organic Chemistry from UCLA in 1992, working in the laboratories of Robert Armstrong and holds a B.S. degree in Chemistry from the University of Connecticut. |
|
Kenneth R. Pitzer, D.V.M.
Kenneth R. Pitzer., D.V.M., joined Theravance in 2002 as Director, New Product Planning, and has held various positions in the Commercial Development Department. He was promoted to Vice President, Strategic and Commercial Planning, in January 2008. Prior to joining Theravance, Dr. Pitzer worked at Lederle Laboratories in sales, marketing research and product management from 1989 to 1995 and then at Cygnus, Inc., from 1995 until 2002, ultimately serving as the Vice President of Product Management. Dr. Pitzer earned a Doctor of Veterinary Medicine degree from The Ohio State University in 1987 and an M.B.A. from Carnegie-Mellon University in 1989. |
Terms of Use Website Admin Contact Theravance Contact Site Map